Pharmaceuticals and Healthcare Reports Japan Dyslipidemia Market Cliquez pour lire
  • Commentaires

Pharmaceuticals and Healthcare Reports

Japan Dyslipidemia Market

Publié sur dans “Santé & Fitness, Santé & Fitness”, langue – English. 3 pages.
The launch of the proprotein convertase subtilisin/kexin type 9 (PCSK9) biologics and the cholesteryl ester transfer protein (CETP) inhibitors will reshape the sales landscape of the dyslipidemia market moving forward. Plus
Afficher les étiquettes
S'abonner GRATUITEMENT

Autres publications de “Pharmaceuticals and Healthcare Reports”

Voir toutes les publications